




The relative strengths and weaknesses of Lyell Immunopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lyell Immunopharma Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 165% points. The greatest weakness of Lyell Immunopharma Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 357%, being 144% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	554,686
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	34,519
Liabilities, Non-Current	60,558
Other Assets	92,689
Other Compr. Net Income	7,505
Other Expenses	-2,790
Other Liabilities	0
Other Net Income	12,376
Other Revenues	130
Property and Equipment	102,654
Research and Development	182,945
Selling, General and Administrative Expense	66,983

Output Variable	Value in 1000 USD
Assets	750,029
Liabilities	95,077
Expenses	247,138
Revenues	130
Stockholders Equity	654,952
Net Income	-234,632
Comprehensive Net Income	-230,880
BaseVar	556,128
ECR before Limited Liability	283%
Economic Capital Ratio	357%